Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + docetaxel
- Development stage
- Unknown
- Lead developer
- Debiopharm
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
oxaliplatin + docetaxel is a combination chemotherapy regimen investigated by the University of Pittsburgh for the treatment of androgen-independent prostate cancer (AIPC). Oxaliplatin is a third-generation platinum-based antineoplastic agent that functions as a DNA alkylator, forming intra- and inter-strand DNA cross-links that inhibit DNA replication and transcription, ultimately leading to cell death. Docetaxel (marketed as Taxotere) is a taxane that acts as a microtubule stabilizer; it binds to tubulin, promoting its assembly into stable microtubules and inhibiting their disassembly, which arrests the cell cycle in the G2/M phase and induces apoptosis. This combination was specifically evaluated in Phase II clinical trials for patients with metastatic prostate cancer who had failed prior cytotoxic chemotherapy regimens.
- Brand names
- Eloxatin + Taxotere
- Other names
- Oxaliplatin and TaxotereOxaliplatin and DocetaxelOxaliplatin + Docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on oxaliplatin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + docetaxel.